File: '\\swfile\EmailIn\20240411 083416 Attachment 2024_04_11 ENBI NR proceeding on NBPP financing.docx'

NOT FOR DISTRIBUTION IN THE UNITED STATES

Entheon Biomedical Announces Private Placement Financing

VANCOUVER, BC, April 11, 2024 - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") announces that it is proceeding on a private placement financing of up to 2,950,000 Units (the "Units") at a price of CDN$0.05 per Unit for gross proceeds of up to CDN$147,500 (the "Placement").

Each Unit will consist of one common share in the capital of the Company (a "Share") and one transferable share purchase warrant (a "Warrant"). Each Warrant will be exercisable to acquire one additional Share at an exercise price of CDN$0.10 per Share for a period of 60 months from the date of issuance.

The Company intends to use the proceeds from the Placement towards general working capital purposes. All securities issued under the Placement will be subject to a four-month and one-day hold period and the Company may pay finder's fees in accordance with the policies of the Canadian Securities Exchange.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

https://entheonbiomedical.com